JNJ-26076713
CAS No. : 669076-03-3
| Size | Price | Stock |
|---|---|---|
| 100 mg | Get quote | |
| 250 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-116030 |
| M.Wt: | 490.64 |
| Formula: | C29H38N4O3 |
| Purity: | >98 % |
| Solubility: | 10 mM in DMSO |
JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization[1].
In Vitro: JNJ-26076713 (5-5000 nM) inhibits FGF2-induced HUVEC migration in a dose-dependent manner[1].
JNJ-26076713 (0.1, 1, and 10 μg) inhibits angiogenesis in the chick chorioallantoic membrane (CAM) model in a dose-dependent manner[1].
In Vivo: JNJ-26076713 (30-120 mg/kg; i.g.; twice daily for 5 days; C57BL/6J mice with oxygen-induced retinopathy (OIR) model) inhibits retinal neovascularization in a dose-dependent manner[1].
JNJ-26076713 (60 mg/kg; i.g.; twice daily for 5 days; diabetic Long-Evans rats) inhibits the increase in retinal vascular permeability and leukostasis associated with diabetes[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- JNJ-26076713
- Cat. No.:
- HY-116030
- Quantity:
Your information is safe with us.